Related Experiment Video
Updated: Mar 31, 2026

Investigating Mast Cell Secretory Granules; from Biosynthesis to Exocytosis
Published on: January 26, 2015
Modulation of host defense peptide-mediated human mast cell activation by LPS
Kshitij Gupta1, Hariharan Subramanian1, Hydar Ali2
1Department of Pathology, University of Pennsylvania School of Dental Medicine, Philadelphia, PA, USA.
Abstract:
Human β-defensin3 (hBD3) and the cathelicidin LL-37 are host defense peptides (HDPs) that directly kill microbes and display immunomodulatory/wound-healing properties via the activation of chemokine, formylpeptide and epidermal growth factor receptors on leukocytes and epithelial cells. A C-terminal 14 amino acid hBD3 peptide with all Cys residues replaced with Ser (CHRG01) and an LL-37 peptide consisting of residues 17-29 (FK-13) display antimicrobial activity but lack immunomodulatory property. Surprisingly, we found that CHRG01 and FK-13 caused Ca(2+) mobilization and degranulation in human mast cells via a novel G protein-coupled receptor known as Mas-related gene-X2 (MrgX2). At local sites of bacterial infection, the negatively charged LPS likely interacts with cationic HDPs to inhibit their activity and thus providing a mechanism for pathogens to escape host defense mechanisms. We found that LPS caused almost complete inhibition of hBD3 and LL-37-induced Ca(2+) mobilization and mast cell degranulation. In contrast, it had no effect on CHRG01 and FK-13-induced mast cell responses. These findings suggest that HDP derivatives that kill microbes, harness mast cell's host defense and wound-healing properties via the activation of MrgX2 but are resistant to inhibition by LPS could be utilized for the treatment of antibiotic-resistant microbial infections.
Insights
New host defense peptide (HDP) derivatives, CHRG01 and FK-13, activate mast cells via Mas-related gene-X2 (MrgX2) independently of lipopolysaccharide (LPS) inhibition, offering potential for antibiotic-resistant infections.
Area of Science:
- Immunology
- Microbiology
- Pharmacology
Background:
- Host defense peptides (HDPs) like human β-defensin3 (hBD3) and cathelicidin LL-37 possess antimicrobial and immunomodulatory functions.
- Modified peptides (CHRG01, FK-13) retain antimicrobial activity but lack immunomodulatory properties.
- Lipopolysaccharide (LPS) from bacteria can inhibit HDPs, aiding pathogen evasion.
Purpose of the Study:
- To investigate the mechanism by which modified HDPs (CHRG01, FK-13) interact with host cells.
- To determine if these modified HDPs are affected by LPS inhibition.
- To explore the therapeutic potential of LPS-resistant HDP derivatives.
Main Methods:
- Calcium (Ca2+) mobilization assays in human mast cells.
- Mast cell degranulation assays.
- Assessment of peptide activity in the presence and absence of LPS.
Main Results:
- CHRG01 and FK-13 induced Ca2+ mobilization and degranulation in human mast cells via Mas-related gene-X2 (MrgX2).
- Unlike native hBD3 and LL-37, CHRG01 and FK-13 activity was not inhibited by LPS.
- These findings highlight a novel LPS-resistant mechanism for HDPs.
Conclusions:
- Modified HDPs activating MrgX2 offer a promising strategy against antibiotic-resistant infections.
- Harnessing mast cell responses via LPS-resistant HDPs could enhance host defense.
- Development of HDP derivatives resistant to LPS inhibition is a viable therapeutic avenue.
Related Concept Videos
Formation of Lipopolysaccharides
Inflammation

